For research use only. Not for therapeutic Use.
AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23)[1].
| Catalog Number | I044033 |
| CAS Number | 2756333-42-1 |
| Synonyms | 5-[4-[(2-ethyl-5-fluoro-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N,6-dimethylpyridine-2-carboxamide |
| Molecular Formula | C23H27FN6O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H27FN6O2/c1-4-16-23(32)28-21-17(27-16)6-5-15(20(21)24)13-29-9-11-30(12-10-29)19-8-7-18(22(31)25-3)26-14(19)2/h5-8H,4,9-13H2,1-3H3,(H,25,31)(H,28,32) |
| InChIKey | HLKLYCUPDHVKKZ-UHFFFAOYSA-N |
| SMILES | CCC1=NC2=C(C(=C(C=C2)CN3CCN(CC3)C4=C(N=C(C=C4)C(=O)NC)C)F)NC1=O |
| Reference | [1]. Martin John Packer, et al. Quinoxaline derivatives as anti-cancer drugs. Patent WO2021260092A1. |
